Woburn, United States
Sanegene Bio, a clinical-stage biotechnology company, is committed to advancing transformative RNAi therapies that address global unmet medical needs. Founded in 2021 by industry veterans with deep expertise in RNA interference, Sanegene Bio leverages its proprietary LEAD™ platform to enable tissue-specific gene silencing with a focus on obesity, cardiometabolic, and autoimmune diseases.
Headquartered in the United States, with R&D operations spanning the U.S. and China, the company’s strategy lies in its fully integrated approach. This multidisciplinary fusion is designed to optimize delivery systems for safe and infrequent subcutaneous dosing, offering a promising edge in the biotechnology sector.
Recently, Sanegene Bio secured a substantial $110 million Series B investment on 01 December 2025. This investment round attracted renowned investors including Qiming Venture Partners, Vivo Capital, Invus, Legend Capital, and Eli Lilly, among others. This financial backing underscores strong confidence in the company's technological capabilities and potential market impact.
